UPC_APP_25212/2025

NOVEL LIPID FORMULATIONS FOR NUCLEIC ACID DELIVERY

Prozessuale & UnteranträgeSonstige prozessualeThe Hague LDGeneric application—

Übersicht Entscheidungen Dokumente Zeitverlauf

Parteien

Kläger

Genevant Sciences GmbH
Arbutus Biopharma Corporation

Vertreter: Markus van Gardingen

Beklagte

Moderna, Inc.(Moderna Group)
ModernaTX, Inc.(Moderna Group)
Moderna Switzerland GmbH(Moderna Group)
Moderna Netherlands B.V.(Moderna Group)
Moderna Biotech Spain SL(Moderna Group)
Moderna Germany GmbH(Moderna Group)
Moderna France SASU(Moderna Group)
Moderna Italy S.R.L.(Moderna Group)
Moderna Belgium S.R.L.(Moderna Group)
Moderna Denmark ApS(Moderna Group)
Moderna Sweden AB(Moderna Group)
Moderna Norway AS(Moderna Group)
Moderna Portugal Unipessoal LDA(Moderna Group)
Moderna Poland SP. Z.O.O.(Moderna Group)
Moderna Biotech UK Limited(Moderna Group)

Vertreter: Ruben Laddé; Joachim Renken

Richter

Margot Elsa KokkeJudge-rapporteur

Patente

EP2279254
EP4241767

CPC-Codes: C07J9/00, A61P31/14, A61K9/1271, C12N15/111, C12N2310/14, C12N15/113, A61K9/1272, A61P35/00, A61K31/713, C12N2320/32, A61P31/12, C12N15/1137…

Sektor: Biotechnology

Ausgang

Nur prozessual

Eingereicht: —

Erste Entscheidung: 4. Juni 2025

Sprache: —